ArticleCancer discovery2019
Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia.
Open access · greenAbstract read
In one paragraph
Article in Cancer discovery, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 272 papers.
0numbers the graph read from it
0cells of the map it votes in
272citing papers in PubMed
37.6field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
272 citing papers in PubMed, 422 citations in OpenAlex.
- XY0206 targets FLT3-dependent resistance states in acute myeloid leukemia.The Journal of clinical investigation · 2026Trial
- Long-term outcomes of azacitidine, venetoclax, and gilteritinib in newly diagnosed FLT3-mutated AML.Blood advances · 2026Trial
- Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia.Cancer research communications · 2025Trial
- Imetelstat-mediated alterations in fatty acid metabolism to induce ferroptosis as a therapeutic strategy for acute myeloid leukemia.Nature cancer · 2024Trial
- Trial
- Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplications.Blood advances · 2022Trial
- Molecular profile of FLT3-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib.Blood advances · 2022Trial
- Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results.Leukemia · 2022Trial
- KRAS Mutations Predict Inferior Post-Remission Outcomes in Newly Diagnosed Acute Myeloid Leukemia With MAPK Pathway Mutations.European journal of haematology · 2026Article
- XY0206: A promising sunitinib-derived FLT3 inhibitor targeting therapy-resistant acute myeloid leukemia.The Journal of clinical investigation · 2026Article
- Adaptor-mediated rewiring of FLT3 signaling engages p38 MAPK to sustain gilteritinib resistance in acute myeloid leukemia.Leukemia · 2026Article
- Very Long Chain Fatty Acid Synthesis is a Targetable Dependency in RAS Pathway Mutant Leukemia.Blood cancer discovery · 2026Article
- Dynamic genetic and nongenetic RAS-pathway activation drives resistance to FLT3 and BCL2 inhibitor therapy.Blood · 2026Article
- The type I FLT3 inhibitor XL999 overrides secondary FLT3-ITD mutations that arise under gilteritinib and quizartinib treatment in acute myeloid leukemia.Molecular biomedicine · 2026Article
- Searching the druggable genome using large language models.Bioinformatics (Oxford, England) · 2026Article
- Quizartinib Resistance Mutations and Treatment Outcomes in Relapsed or Refractory FLT3-ITD-Positive AML.Cancer science · 2026Article
- Review
- Targeting oncogenic FLT3 uncovers a ferroptosis vulnerability through selenocysteine recoding in acute myeloid leukaemia.Nature cell biology · 2026Article
- Sphingosine-1-phosphate receptor modulators resensitize FLT3-ITD acute myeloid leukemia cells with NRAS mutations to FLT3 inhibitors.Leukemia · 2026Article
- Review
212 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
21 authors at 7 institutions in 3 countries.
Christine M McMahonDivision of Hematology-Oncology, University of Pennsylvania, Philadelphia, Pennsylvania.
Timothy FerngDivision of Hematology and Oncology, University of California, San Francisco, San Francisco, California.
Jonathan CanaaniHematology Division, Chaim Sheba Medical Center, Tel Aviv University, Tel-Hashomer, Israel.
Eunice S WangRoswell Park Comprehensive Cancer Center, Buffalo, New York.
Jennifer J D MorrissetteDepartment of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.ORCID 0000-0001-9460-7177
Dennis J EastburnMission Bio, San Francisco, California.
Maurizio PellegrinoMission Bio, San Francisco, California.ORCID 0000-0002-2838-2157
Robert Durruthy-DurruthyMission Bio, San Francisco, California.
Christopher D WattDepartment of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Saurabh AsthanaHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California.
Elisabeth A LasaterDivision of Hematology and Oncology, University of California, San Francisco, San Francisco, California.
RosaAnna DeFilippisDivision of Hematology and Oncology, University of California, San Francisco, San Francisco, California.
Cheryl A C PeretzDivision of Hematology and Oncology, University of California, San Francisco, San Francisco, California.
Lisa H F McGaryDivision of Hematology and Oncology, University of California, San Francisco, San Francisco, California.
Safoora DeihimiDepartment of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Aaron C LoganDivision of Hematology and Oncology, University of California, San Francisco, San Francisco, California.
Selina M LugerDivision of Hematology-Oncology, University of Pennsylvania, Philadelphia, Pennsylvania.
Neil P ShahDivision of Hematology and Oncology, University of California, San Francisco, San Francisco, California.
Martin Carroll *Division of Hematology-Oncology, University of Pennsylvania, Philadelphia, Pennsylvania.
Catherine C Smith *Division of Hematology and Oncology, University of California, San Francisco, San Francisco, California.
Alexander E Perl *Division of Hematology-Oncology, University of Pennsylvania, Philadelphia, Pennsylvania. Alexander.perl@uphs.upenn.edu.ORCID 0000-0002-1463-2231
University of California, San Francisco · USUniversity of Pennsylvania · USMission Bio (United States) · USRoswell Park Comprehensive Cancer Center · USSheba Medical Center · ILUCSF Helen Diller Family Comprehensive Cancer Center · USVeterans Health Administration · US
Funding
NRSA Training CoreTL1TR001880 · NCATS · UNIVERSITY OF PENNSYLVANIA · PI MEAGHER, EMMA ANNE · 2016 to 2025
$10.0MUnderstanding and Targeting Chemotherapy Resistance in Acute Myeloid LeukemiaR01CA198089 · NCI · UNIVERSITY OF PENNSYLVANIA · PI CARROLL, MARTIN · 2015 to 2019
$3.3MMechanisms of resistance to clinically-effective FLT3 kinase inhibitors in AMLR01CA166616 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SHAH, NEIL P · 2012 to 2016
$1.6MInvestigating Resistance to FLT3 Inhibitors in AMLK08CA187577 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SMITH, CATHERINE CHOY · 2014 to 2017
$703kHow Does FLT3 Mutation Regulate Myeloid Differentiation in Acute Myeloid LeukemiaR21CA198621 · NCI · UNIVERSITY OF PENNSYLVANIA · PI CARROLL, MARTIN · 2015 to 2016
$396kNCATS NIH HHS TL1 TR001880NCI NIH HHS K08 CA187577NCI NIH HHS R01 CA166616NCI NIH HHS R01 CA198089NCI NIH HHS R21 CA198621
Abstract
Gilteritinib is a potent and selective
Indexed as
Drug Resistance, NeoplasmAdultAgedAged, 80 and overAniline CompoundsClonal EvolutionFemalefms-Like Tyrosine Kinase 3High-Throughput Nucleotide SequencingHumansLeukemia, Myeloid, AcuteMaleMiddle AgedMutationProtein Kinase InhibitorsPyrazinesAniline CompoundsFLT3 protein, humanfms-Like Tyrosine Kinase 3gilteritinibProtein Kinase InhibitorsPyrazinesras Proteins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.